Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dose Finding in Japanese Subjects
NCT00591786Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2005
- Primary completion
- Aug 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Sugammadex in neuromuscular blockade (NMB) (10 arms), sponsored by Merck & Co. Primary endpoint: Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.9 for Train-Of-Four (TOF) Stimulation. Started Dec 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00591786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591786.